A Dual‐Function CD47‐Targeting Nano‐Drug Delivery System Used to Regulate Immune and Anti‐Inflammatory Activities in the Treatment of Atherosclerosis
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202400752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Huanhuan Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China. Hauptthemen laut MEDLINE: Atherosclerosis, CD47 Antigen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Haihe Laboratory of Sustainable Chemical Transformations.
Abstract (Originalsprache)
Atherosclerosis is a primary contributor to cardiovascular disease. Current studies have highlighted the association between the immune system, particularly immune cells, and atherosclerosis, although treatment options and clinical trials remain scarce. Immunotherapy for cardiovascular disease is still in its infancy. Bruton's tyrosine kinase (BTK), widely expressed in various immune cells, represents a promising therapeutic target for atherosclerosis by modulating the anti‐inflammatory function of immune cells. This study introduces a polydopamine‐based nanocarrier system to deliver the BTK inhibitor, ibrutinib, to atherosclerotic plaques with an active targeting property via an anti‐CD47 antibody. Leveraging polydopamine's pH‐sensitive reversible disassembly, the system offers responsive, controlled release within the pathologic microenvironment. This allows precise and efficient ibrutinib delivery, concurrently inhibiting the activation of the NF‐κB pathway in B cells and the NLRP3 inflammasome in macrophages within the plaques. This treatment also modulates both the immune cell microenvironment and inflammatory conditions in atherosclerotic lesions, thereby conveying promising therapeutic effects for atherosclerosis in vivo. This strategy also provides a novel option for atherosclerosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China.
- Nanozyme Medical Center, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
- Tianjin Key Laboratory of Molecular Recognition and Biosensing, College of Chemistry, Nankai University, Tianjin, 300071, China.
ORCID-Profile: Runze Zhao, Yongjian Wang
Förderung
- National Natural Science Foundation of China
- Haihe Laboratory of Sustainable Chemical Transformations
Zitieren
APA
Wang, H., Zhao, R., Peng, L., Yu, A., & Wang, Y. (2024). A Dual‐Function CD47‐Targeting Nano‐Drug Delivery System Used to Regulate Immune and Anti‐Inflammatory Activities in the Treatment of Atherosclerosis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400752
Vancouver
Wang H, Zhao R, Peng L, Yu A, Wang Y. A Dual‐Function CD47‐Targeting Nano‐Drug Delivery System Used to Regulate Immune and Anti‐Inflammatory Activities in the Treatment of Atherosclerosis. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400752
BibTeX
@article{Wang2024,
author = {Wang, Huanhuan and Zhao, Runze and Peng, Lei and Yu, Ao and Wang, Yongjian},
title = {A Dual‐Function CD47‐Targeting Nano‐Drug Delivery System Used to Regulate Immune and Anti‐Inflammatory Activities in the Treatment of Atherosclerosis},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202400752}
}
EUVIMED